Literature DB >> 12193921

Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks?

Paul L Doering1, Lisa A Boothby, Meyling Cheok.   

Abstract

Evidence-based medicine that is designed to guide benefit/risk drug therapy decisions does not exist for pregnant women. The types of studies that do exist are usually conducted in animals, which may not reflect human benefits and risks. The types of studies that do exist in humans are typically limited and, at best, may show an "association" between a particular drug therapy and an undesirable effect. This review outlines the difficulties that are associated with the assessment of the benefits/risks of drug therapy during pregnancy, the history of the Food and Drug Administration regulations for labeling prescription drugs, and the strengths and weaknesses of the current Food and Drug Administration pregnancy labeling system. Proposed changes to the current system are reviewed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193921     DOI: 10.1067/mob.2002.125740

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  20 in total

1.  Assessment of foetal risk associated with 93 non-US-FDA approved medications during pregnancy.

Authors:  Ahmed H Al-Jedai; Sakra S Balhareth; Roaa A Algain
Journal:  Saudi Pharm J       Date:  2012-05-19       Impact factor: 4.330

2.  FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?

Authors:  Ruth Law; Pina Bozzo; Gideon Koren; Adrienne Einarson
Journal:  Can Fam Physician       Date:  2010-03       Impact factor: 3.275

3.  Disparities in Self-Reported Prenatal Counseling: Does Immigrant Status Matter?

Authors:  Tiffany L Green; Mandar V Bodas; Heather A Jones; Saba W Masho; Nao Hagiwara
Journal:  J Community Health       Date:  2018-10

Review 4.  Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.

Authors:  Sílvia M Illamola; Christina Bucci-Rechtweg; Maged M Costantine; Ekaterini Tsilou; Catherine M Sherwin; Anne Zajicek
Journal:  Br J Clin Pharmacol       Date:  2017-10-22       Impact factor: 4.335

Review 5.  Challenges in conducting clinical research studies in pregnant women.

Authors:  Monique McKiever; Heather Frey; Maged M Costantine
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-04-18       Impact factor: 2.745

6.  Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program.

Authors:  Kristine E Shields; Bengt-Erik Wiholm; Linda S Hostelley; Linda F Striano; Sam R Arena; Robert G Sharrar
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

7.  Using the electronic medical record to assess contraception usage among women taking category D or X medications.

Authors:  Sheila K Mody; John Paul Farala; Jennifer Wu; Robert Felix; Christina Chambers
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-08-25

8.  Prescription of hazardous drugs during pregnancy.

Authors:  Heli Malm; Jaana Martikainen; Timo Klaukka; Pertti J Neuvonen
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov.

Authors:  Chris Stockmann; Catherine M T Sherwin; Gideon Koren; Sarah C Campbell; Jonathan E Constance; Matthew Linakis; Alfred Balch; Michael W Varner; Michael G Spigarelli
Journal:  J Clin Pharmacol       Date:  2013-11-14       Impact factor: 3.126

Review 10.  Is personalized medicine achievable in obstetrics?

Authors:  Sara K Quinney; Avinash S Patil; David A Flockhart
Journal:  Semin Perinatol       Date:  2014-10-03       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.